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Abstract
In 2016, 3209 heart transplants were performed in the United States.
New, active listings increased 57% since 2005. The number of adult heart
transplant survivors continued to increase, and in 2016, 30,622 recipients
were living with heart transplants. Patient mortality following transplant
has declined. The number of pediatric candidates and transplants per-
formed also increased. New listings for pediatric heart transplants in-
creased from 454 in 2005 to 624 in 2016. The number of pediatric heart
transplants performed each year increased from 319 in 2005 to 445 in
2016. Among pediatric patients who underwent transplant in 2015, death
occurred in 5.9% at 6 months and 7.2% at 1 year.
Keywords: End-stage heart failure, heart transplant, transplant outcomes,
ventricular assist device.
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 1 Introduction
Since the first heart transplant was performed in the US in 1968, heart transplantation
has transitioned from a high-risk experimental procedure to a lifesaving surgery that
affords good outcomes and longevity for patients with end-stage heart failure. Sur-
vival after heart transplant continues to improve. In addition, patients are surviving
long enough to undergo transplant in large part due to mechanical circulatory sup-
port. Ventricular assist devices (VADs) have evolved substantially and are currently de-
signed to improve function and longevity. The improved devices and their acceptance
as safe bridges to transplant correspond to an increase in the number of candidates
listed with mechanical circulatory support. Over one-half of adult heart transplant
recipients in 2016 had a VAD at the time of transplant. The proportion of patients un-
dergoing transplant as status 1A and with a VAD has increased substantially. In 2016,
the OPTN Board of Directors approved revisions to the heart allocation policy that
were designed to more equitably stratify patients and to account for various manage-
ment strategies. These modifications to the policy will be implemented in 2018. In
this report, we discuss the most significant trends in heart transplantation over the
past decade.
2 Adult Heart Transplant
2.1 Waitlist Trends: New Listings, Time to Transplant, and Waitlist Mortality
Between 2005 and 2016, the number of new active listings for heart transplant in-
creased 57%, from 2240 to 3521 (Figure HR 1). The number of candidates actively
awaiting heart transplant increased dramatically over the same period, from 1262 to
2862 (Figure HR 2), an increase of 127%, suggesting that transplant rates have not
increased at the same rate as listings. The most remarkable demographic trends in
heart transplant include the following: a steady increase in the proportion of heart
transplant candidates aged 65 years or older, from 11.9% in 2005 to 18.0% in 2016,
with a slight decrease in all other age groups (Figure HR 3); an increase in the propor-
tion of black candidates from 16.4% to 24.9% (Figure HR 4); a decline in the proportion
of candidates with coronary artery disease as the etiology for transplant from 41.4%
to 32.0%, and an increase in cardiomyopathy from 45.5% to 58.1% (Figure HR 5). The
proportion of candidates with extended waiting times decreased. In 2005, 16.2% of
candidates waited 5 or more years; this proportion gradually declined to 4.3% in 2016
(Figure HR 6). The proportion of candidates awaiting transplant as status 1A doubled
to 44.5% in 2016 (Figure HR 7). The proportion of status 1B candidates increased sim-
ilarly, while those waiting at status 2 declined from 33.4% to 16.2%. The proportion
of candidates with VADs at listing more than tripled in this time period, from 8.9% to
31.7% (Figure HR 8). Notably, sex distribution did not change (Figure HR 9).
Between 2005 and 2016, overall heart transplant rates declined 27.8% from 129.0
to 93.1 per 100 waitlist years (Figure HR 13). Similar reductions occurred for all age
groups, blood types, and status groups (Figure HR 11, Figure HR 12, Figure HR 13).
Transplant rates peaked for all groups in 2006 and 2007, and reached a nadir in 2014
and 2015. The highest transplant rates were consistently for candidates aged 65 years
or older (113.1 per 100 waitlist years), in blood group AB (302.5 per 100 waitlist years),
and at status 1A (488.1 per 100 waitlist years). Transplant rates by age group were
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 similar, but varied widely by blood type and medical urgency status. Blood type O
candidates underwent transplant at a rate of 64.7 per 100waitlist years in 2016, nearly
half the rate of blood type A and B candidates and 20% of the rate of blood type AB
candidates. By status group, transplant rates for status 1B and status 2 candidates
declined substantially, from 216.4 to 48.6 per 100 waitlist years, and from 51.0 to 7.4
per 100 waitlist years, respectively.
Concurrent events that may have affected this trend include the OPTN policy al-
lowing patients with LVADs to be listed as status 1A for 30 days; the OPTN broader
sharing policy, which changed the heart allocation sequence to prioritize zone A sta-
tus 1A and 1B candidates over local status 2 candidates, approved by the OPTN Board
of Directors in 2002 and 2006, respectively; and the 2008 Food and Drug Administra-
tion approval of the HeartMate II LVAD as a bridge to transplant. The broader sharing
policy may have resulted in more higher-urgency candidates undergoing transplant.
LVADs offer stability on the waiting list, which may have resulted in increased selec-
tivity in choosing organs. The median waiting time in 2015-2016 was 9.4 months,
an increase from 4.2 months in 2005-2006 (Figure HR 15). Waiting times peaked in
2013-2014, then declined again. In 2015-2016, median waiting time was longest for
blood type O candidates, 17.2 months (Figure HR 16), and 13.6 months for candi-
dates with body mass index ≥ 31 kg/m2 (Figure HR 18). Women waited on average
7.5months, andmen 10.0months (Figure HR 15). Status 2 candidates had the longest
median waiting times, 23.6 months in 2013-2014; fewer than half of status 2 candi-
dates underwent transplant in 2015-2016, andmedian waiting time was not observed
(Figure HR 17). Geographic variability in access to donor hearts remained. Overall,
51.1% of candidates listed in 2015 underwent transplant within 1 year (Figure HR 19);
however, the proportion of candidates undergoing transplant within this time frame
varied from 15.4% to 100% depending on the donation service area (DSA) (Figure HR
20). Among the 52 DSAs with more than 10 candidates, the proportion of candidates
undergoing transplant in less than 1 year ranged from 18.8% to 69.8%.
Among candidates listed in 2013, 51.9% underwent transplant during the first year
on the waiting list, 32.7%were still waiting, 8.1%were removed from the list, and 7.2%
had died (Figure HR 14). At 3 years, 9.5% had died, 15.6% had been removed from the
list, 65.6% had undergone transplant, and 9.4%were still waiting. Thus, within 3 years,
most patients undergo transplant and less than 10% die on the waiting list.
Since 2005, pretransplant mortality on the waiting list steadily declined, from 14.6
to 9.7 deaths per 100 waitlist years in 2015-2016. Declines occurred in all age groups
and racial/ethnic groups except Asians, whose mortality declined to 9.2 deaths per
100 waitlist years in 2011-2012 and increased to 13.0 deaths per 100 waitlist years in
2015-2016 (Figure HR 21, Figure HR 22). Pretransplant mortality declined notably for
candidates with VADs at listing, from 43.2 to 8.0 deaths per 100 waitlist years, lower
than the pretransplantmortality among candidateswithout VADs (10.4 deaths per 100
waitlist years) (Figure HR 26). Pretransplant mortality declined precipitously among
status 1A and 1B candidates, from 76.9 deaths per 100 wait-list years in 2005-2006
to 17.3 in 2015-2016, and from 21.3 deaths per 100 waitlist years to 3.4, respectively
(Figure HR 25). Of note, pretransplant mortality for status 2 candidates was similar to
that for status 1B candidates, 3.1 and 3.4 deaths per 100 waitlist years in 2015-2016,
respectively. Inactive candidates made up one of the few subgroups with fairly con-
sistent increases in pretransplant mortality over the past 10 years, 25.3 deaths per
100 waitlist years in 2015-2016, compared with 16.4 in 2005-2006. Among candidates
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 with known indications for transplant, pretransplant mortality was highest for those
with valvular heart disease (Figure HR 24).
Wide variation in pretransplant mortality by DSA persisted, ranging from 3.4 to
19.9 deaths per 100 waitlist years (Figure HR 27). Deaths within 6 months of removal
from the waiting list fluctuated over the past decade, peaking at 33.4% in 2013 and
declining to 21.8% in 2016 (Figure HR 28). Mortality within 6 months of removal from
the waiting list remained highest for candidates listed as status 1A.
2.2 Donor Trends
The overall deceased heart donation rate was 2.9 per 1000 deaths, but it varied by
state, ranging from 0.37 to 6.16 per 1000 deaths (Figure HR 31). Almost half of donors,
49.8%, were aged 18 to 34 years (Figure HR 29) and 63.1% were white (Figure HR
30). Rates of hearts recovered for transplant but not transplanted reached a nadir
in 2009-2010 and have trended upward since (Figure HR 32). In 2015-2016, 1.0% of
recovered hearts were not transplanted. The increase is most notable for donors
aged 50 years or older.
Head trauma remained the most common cause of death among heart donors,
although the proportion declined substantially since 2005, from 63.2% of deceased
donors to 45.5% in 2016. Donation after deaths due to anoxia tripled since 2005, to
36.0% of heart donors in 2016 (Figure HR 33).
2.3 Overall Trends in Heart Transplant
In 2016, 3209 heart transplants were performed; 445 were in pediatric recipients and
2764 in adult recipients (Figure HR 34). Overall, heart transplants increased in all age
groups, but recipients aged 65 years or older represent a growing proportion, from
9.7% in 2005 to 17.4% in 2016 (Figure HR 35). The proportion of recipients who under-
went transplant as status 1A increased from 39.5% in 2005 to 69.1%in 2016. In 2005,
26.3% of recipients were status 2, but only 2.3% in 2016; 75 underwent transplant as
status 2 (Figure HR 39). In 2016, most heart transplant recipients were aged 50-64
years (Figure HR 35). The typical recipient remained white, male, with blood type A or
O, although increasing proportions of recipients are non-white.
In 2016, 52.2% of recipients received induction therapy (Figure HR 40). In 2005,
40.4% of recipients were receiving cyclosporine at the time of transplant; this declined
to 2.3% in 2016, and was largely replaced by tacrolimus, used by 93.1% of recipients
(Figure HR 41).
Transplant program volume has grown since 2005; the median transplant volume
increased from 12 transplants per year in 2005 to 21 in 2016. Although numbers
of transplants performed have generally increased, 25% of programs still perform
10 per year or fewer. Most programs perform between 11 and 64 transplants per
year (Figure HR 47). In 2016, 41.1% of transplants were performed at programs in
the 25th-75th volume percentile and 41.6% at programs in the 75th-95th percentile
(Figure HR 48).
2.4 Posttransplant Survival and Morbidity
Overall one-year survival for patients who underwent heart transplant in 2009-2011
was 90.1%, 3-year survival was 83.5%, and 5-year survival 78.3% (Figure HR 51). One-
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 year survival among most subgroups was similar, but tended to be lower among re-
cipients aged 65 years or older (Figure HR 49) and black recipients (Figure HR 50).
Conversely, 1-year survival was higher for recipients aged 18-34 years (94.4%) and
Asians (92.1%). By 5 years, survival was 76.6% for recipients aged 65 years or older
and 73.8% for black recipients. Notably, although similar to recipients with ventricular
assist devices at 1 and 3 years, survival for recipients with intra-aortic balloon pumps
declined after year 3 to 75.3% at year 5 (Figure HR 52). Survival did not differ mean-
ingfully between the medical urgency categories at any time, but tended to be lower
for status 1A recipients at years 3 and 5 (Figure HR 54). Survival after heart transplant
continued to improve. Since 2005, patient death after transplant decreased overall
at 6 months and at 1, 3, and 5 years, despite slight increases in 6-month and 1- and
3-year mortality between 2011 and 2014 (Figure HR 55). The number of heart trans-
plant survivors has increased since 2005. On June 30, 2016, 30,622 heart transplant
recipients were alive with a functioning graft; most had undergone transplant at age
50 years or older (Figure HR 56).
The incidence of acute rejection in the first year posttransplant decreased from
23.8% among recipients who underwent transplant 2010-2011 to 23.3% among re-
cipients who underwent transplant in 2014-2015 (Figure HR 57). Acute rejections in
recipients aged 65 years or older increased slightly since 2010-2011. Posttransplant
lymphoproliferative disorder (PTLD) remained uncommon, with an overall cumulative
incidence of only 1.1% by 5 years posttransplant (Figure HR 58). The most common
documented cause of death in the first posttransplant year was infection (Figure HR
59). By the second year, cardiovascular/cerebrovascular disease was the leading doc-
umented cause of death through year 5 (Figure HR 60). Malignancy was relatively
infrequent as a cause of death, 1.6% of deaths at 5 years.
3 Pediatric Heart Transplant
3.1 Pediatric Waitlist Trends
In 2016, 624 new pediatric candidates were added to the heart transplant waiting list,
with few at inactive status (Figure HR 61). At year-end 2016, 367 candidates listed
before their eighteenth birthdays were awaiting heart transplant, 69.8% active (Fig-
ure HR 62). Over the past decade, the number of candidates listed as inactive status
decreased from 178 in 2006 to 111 in 2016. The largest pediatric age group on the
waiting list in 2016 was 11-17 years (34.2%), followed by ages younger than 1 year
(27.7%), 1-5 years (23.4%), and 6-10 years (14.7%) (Figure HR 63). Over half of heart
transplant candidates were white, 20.7% were Hispanic, 20.6% were black, and 3.0%
were Asian (Figure HR 64). Considering trends over time, the proportion of waitlist
candidates aged younger than 1 year increased from 12.4% on December 31, 2006,
to 16.2% on December 31, 2016 (Table HR 11). The proportion of male candidates
remained high, 55.7%. The proportion of white candidates decreased from 60.2% on
December 31, 2006, to 51.4% on December 31, 2016. For candidates waiting on De-
cember 31, 2016, congenital defect was the leading cause of heart disease (55.4%), up
from 39.4% in 2006 (Table HR 12). The proportion of status 1A candidates at any time
during the year increased from 49.5% in 2006 to 69.2% in 2015, then decreased to
60.8% in 2016 (Figure HR 67). The proportion of status 1B candidates increased from
9.8% in 2015 to 14.3% in 2016. The differences in status 1A and 1B listing percent-
5
  
 ages from 2015 to 2016 are likely due to changes to pediatric heart allocation policy
implemented in March 2016. The percentage of candidates using VADs at the time
of listing increased from 3.2% in 2006 to 6.1% in 2016 (Table HR 12). Proportions of
heart-only candidates increased from 91.2% at year-end 2006 to 99.4% at year-end
2016, and candidates for heart-lung and heart-kidney transplants decreased to less
than 1% (Table HR 13). Among the 627 candidates removed from the waiting list in
2016, 460 (73.4%) were removed due to undergoing transplant, 60 (9.6%) died, 59
(9.4%) were removed due to improved condition, and 29 (4.6%) were considered too
sick to undergo transplant (Table HR 15).
Just over 70% of candidates newly listed in 2013 underwent transplant within 3
years, 10.7% died, 13.7% were removed from the list, and 4.6% were still waiting (Fig-
ure HR 68). The rate of heart transplants among active pediatric waitlist candidates
decreased fromapeak of almost 300 per 100waitlist years in 2006 to 183 per 100wait-
list years in 2016 (Figure HR 69). Transplant rates varied by age, with the highest rates
for candidates aged younger than 1 year, at 309 transplants per 100 waitlist years
in 2016, followed by candidates aged 11-17 years, at 189 transplants per 100 waitlist
years (Figure HR 69). Pretransplant mortality slowly declined from 27.1 deaths per
100 waitlist years in 2005-2006 to 19.1 in 2015-2016 (Figure HR 70). The pretransplant
mortality rate was highest for candidates aged younger than 1 year, at 56.8 deaths
per 100 waitlist years in 2015-2016, an increase from its nadir of 44.9 in 2013-2014;
pretransplant mortality was 14.6 deaths per 100 waitlist years for candidates aged
1-5 years, 14.1 for ages 6-10 years, and 8.2 for ages 11-17 years (Figure HR 70). By
race, pretransplant mortality was highest in 2015-2016 for white candidates at 23.4
deaths per 100 waitlist years, followed by black and Hispanic candidates at 17.6 and
9.4, respectively (Figure HR 71). Regarding cause of disease, pretransplant mortality
was highest for candidates with dilated myopathy/myocarditis or congenital defects
(Figure HR 72). By status, pretransplantmortality was highest for status 1A candidates
(33.0 deaths per 100 waitlist years) and inactive candidates (27.8), compared with 3.0
and 1.8 for status 1B and status 2 candidates, respectively (Figure HR 73).
3.2 Pediatric Transplant
Pediatric transplant recipients are those aged 18 years or younger at the time of trans-
plant; the category excludes candidates listed before their 18th birthdays who under-
went transplanted afterward. The number of pediatric heart transplants performed
each year increased from 319 in 2005 to 445 in 2016 (Figure HR 74). In 2016, 26 of 135
total heart transplant programs performed pediatric heart transplants exclusively, 78
performed adult heart transplants, and 27 performed both adult and pediatric heart
transplants (Fig HR 75). In 2016, 8.5% of transplants in recipients aged younger than
15 years were performed at programs with volume of 5 or fewer pediatric transplants
in that year (Fig HR 76). Over the past decade, the age, sex, and race of pediatric
heart transplant recipients changed little (Table HR 16). Congenital defects remained
the most common primary cause of disease, affecting 48.1% of recipients who un-
derwent transplant in 2014-2016 (Table HR 17). The proportion of ABO-incompatible
transplants in 2014-2016 was 5.4%, increased from 2.7% a decade earlier (Table HR
18). The proportion of patientswhounderwent transplant as status 1A increased from
71.6% in 2004-2006 to 84.8% in 2014-2016. VAD use doubled from10.5%of transplant
recipients in 2004-2006 to 23.7% in 2014-2016 (Table HR 17).
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 3.3 Pediatric Immunosuppression and Outcomes
In 2016, the most common induction therapy was T-cell depleting agents, used in
70.2% of heart transplant recipients, followed by interleukin-2 receptor antagonists
(IL-2-RA) in 9.3%. No induction therapy was reported in 21.8% of recipients (Figure HR
77). T-cell depleting agents were generally used more frequently for the most sensi-
tized patients, while IL-2-RA was used less frequently for sensitized patients (Figure
HR 82). The initial immunosuppression agents used most commonly in 2016 were
tacrolimus (93.2%, Figure HR 78), mycophenolate (93.4%, Figure HR 79), and steroids
(63.0%, Figure HR 81). In 2014, mammalian target of rapamycin inhibitors were used
in only 1.8% of recipients at the time of transplant, but use increased to 11.2% at
1 year posttransplant (Figure HR 80). Among patients who underwent transplant in
2015, steroid use was 60.2% at transplant and 60.0% at 1 year posttransplant (Figure
HR 81).
Among pediatric heart transplant recipients 2014-2015, the rate of acute rejection
in the first year was 20.2% overall with the highest rate observed, 24.0%, in the 6-10
year age group; rates of rejection were 20.9% for ages 11-17 years and 18.7% for
ages younger than 6 years (Figure HR 84). Among pediatric heart transplant recipients
2012-2016, 34.7% were cytomegalovirus (CMV) negative and 44.5% were Epstein-Barr
virus (EBV) negative (Table HR 20). The combination of a CMV-positive donor and CMV-
negative recipient occurred in 17.0% of transplants; for EBV, this occurred in 29.0% of
transplants (Table HR 20).
Recipient death occurred in 6.5% at 6 months and in 8.4% at 1 year among heart
transplants performed in 2014-2015, in 10.2% at 3 years for transplants performed in
2012-2013, in 16.2% at 5 years for transplants performed in 2010-2011, and in 34.1%
at 10 years for transplants performed in 2004-2005 (Figure HR 86). Overall, 1-year and
5-year patient survival was 89.3% and 78.7%, respectively, among recipients who un-
derwent transplant in 2004-2011 (Figure HR 87). By age, 5-year patient survival was
73.7% for recipients aged younger than 1 year, 79.9% for ages 1-5 years, 87.5% for
ages 6-10 years, and 78.9% for ages 11-17 years (Figure HR 87). The leading identi-
fied causes of death in the first 5 years posttransplant were cardio/cerebrovascular
disease (4.6%) and graft failure (3.3%) (Figure HR 89).
The incidence of PTLD among EBV-negative recipients was 5.2% at 5 years post-
transplant, compared with 2.6% among EBV-positive recipients (Figure HR 85).
7
  
 The publication was produced for the U.S. Department of Health andHuman Services,
Health Resources and Services Administration, by the Minneapolis Medical Research
Foundation (MMRF) and by the United Network for Organ Sharing (UNOS) under con-
tracts HHSH250201500009C and 234-2005-37011C, respectively.
This publication lists non-federal resources in order to provide additional informa-
tion to consumers. The views and content in these resources have not been formally
approved by the U.S. Department of Health and Human Services (HHS) or the Health
Resources and Services Administration (HRSA). Neither HHS nor HRSA endorses the
products or services of the listed resources.
OPTN/SRTR 2016 Annual Data Report is not copyrighted. Readers are free to dupli-
cate and use all or part of the information contained in this publication. Data are not
copyrighted and may be used without permission if appropriate citation information
is provided.
Pursuant to 42U.S.C. §1320b-10, this publicationmaynot be reproduced, reprinted,
or redistributed for a fee without specific written authorization from HHS.
Suggested Citations Full citation: Organ Procurement and Transplantation Net-
work (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2016
Annual Data Report. Rockville, MD: Department of Health andHuman Services, Health
Resources and Services Administration; 2017. Abbreviated citation: OPTN/SRTR 2016
Annual Data Report. HHS/HRSA.
Publications based on data in this report or supplied on request must include a
citation and the following statement: The data and analyses reported in the 2016 An-
nual Data Report of the U.S. Organ Procurement and Transplantation Network and
the Scientific Registry of Transplant Recipients have been supplied by the United Net-
work for Organ Sharing and theMinneapolisMedical Research Foundation under con-
tract withHHS/HRSA. The authors alone are responsible for reporting and interpreting
these data; the views expressed herein are those of the authors and not necessarily
those of the U.S. Government.
This report is available at srtr.transplant.hrsa.gov. Individual chapters, as well as
the report as a whole, may be downloaded.
8
  
 
2004 2006 2008 2010 2012 2014 2016
Year
0
10
00
30
00
Ca
nd
ida
tes Active
Inactive
All
Figure HR 1. New adult candidates added to the heart transplant wait-
ing list. A new candidate is one who first joined the list during the given year,
without having been listed in a previous year. Previously listed candidateswho
underwent transplant and subsequently relisted are considered new. Candi-
dates concurrently listed at multiple centers are counted once. Active and in-
active patients are included.
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Figure HR 2. Adults listed for heart transplant on December 31 each year.
Candidates concurrently listed at multiple centers are counted once. Those
with concurrent listings and active at any program are considered active.
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Figure HR 3. Distribution of adults waiting for heart transplant by age.
Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Age is determined
at the later of listing date or January 1 of the given year. Active and inactive
candidates are included.
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Figure HR 4. Distribution of adults waiting for heart transplant by race.
Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Active and inactive
candidates are included.
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Figure HR 5. Distribution of adults waiting for heart transplant by diag-
nosis. Candidates waiting for transplant at any time in the given year. Can-
didates listed concurrently at multiple centers are counted once. Active and
inactive patients are included. CAD, coronary artery disease.
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FigureHR6. Distributionof adultswaiting for heart transplant bywaiting
time. Candidates waiting for transplant at any time in the given year. Candi-
dates listed concurrently at multiple centers are counted once. Time on the
waiting list is determined at the earlier of December 31 or removal from the
waiting list. Active and inactive candidates are included.
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Figure HR 7. Distribution of adults waiting for heart transplant by medi-
cal urgency. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Medical
urgency status is the most severe during the year. Active and inactive patients
are included.
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Figure HR 8. Distribution of adults waiting for heart transplant by VAD
status at listing. Candidates waiting for transplant at any time in the given
year. Candidates listed concurrently at multiple centers are counted once.
Active and inactive patients are included. VAD, ventricular assist device.
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Figure HR 9. Distribution of adults waiting for heart transplant by sex.
Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Active and inactive
patients are included.
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Figure HR 10. Distribution of adults waiting for heart transplant by blood
type. Candidates waiting for transplant at any time in the given year. Can-
didates listed concurrently at multiple centers are counted once. Active and
inactive patients are included.
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Figure HR 11. Deceased donor heart transplant rates among active adult
waitlist candidates by age. Transplant rates are computed as the number
of deceased donor transplants per 100 patient-years of active wait time in a
given year. Individual listings are counted separately. Age is determined at
the later of listing date or January 1 of the given year. Rates with less than 10
patient-years of exposure are not shown.
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Figure HR 12. Deceased donor heart transplant rates among active adult
waitlist candidates by blood type. Transplant rates are computed as the
number of deceased donor transplants per 100 patient-years of active wait
time in a given year. Individual listings are counted separately. Rates with less
than 10 patient-years of exposure are not shown.
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Figure HR 13. Deceased donor heart transplant rates among active adult
waitlist candidates by medical urgency. Transplant rates are computed as
the number of deceased donor transplants per 100 patient-years of activewait
time in a given year. Individual listings are counted separately. Rates with less
than 10 patient-years of exposure are not shown.
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Figure HR 14. Three-year outcomes for adults waiting for heart trans-
plant, new listings in 2013. Adults waiting for heart transplant and first listed
in 2013. Candidates concurrently listed at more than one center are counted
once, from the time of earliest listing to the time of latest removal. DD, de-
ceased donor.
15
  
 
2005-06 2009-10 2013-14
Year of listing
4
6
8
10
12
14
Mo
nth
s
Male
Female
All
Figure HR 15. Medianmonths to heart transplant for waitlisted adults by
sex. Observations censored on December 31, 2016; Kaplan-Meier competing
riskmethods used to estimate time to transplant. Analysis performed per can-
didate, not per listing. If an estimate is not plotted, 50% of the cohort listed in
that year had not undergone transplant by the censoring date. Only the first
transplant is counted.
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Figure HR 16. Median months to heart transplant for waitlisted adults
by blood type. Observations censored on December 31, 2016; Kaplan-Meier
competing risk methods used to estimate time to transplant. Analysis per-
formed per candidate, not per listing. If an estimate is not plotted, 50% of the
cohort listed in that year had not undergone transplant by the censoring date.
Only the first transplant is counted.
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Figure HR 17. Medianmonths to heart transplant for waitlisted adults by
medical urgency at listing. Observations censored on December 31, 2016;
Kaplan-Meier competing risk methods used to estimate time to transplant.
Analysis performed per candidate, not per listing. If an estimate is not plot-
ted, 50% of the cohort listed in that year had not undergone transplant by the
censoring date. Only the first transplant is counted.
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Figure HR 18. Median months to heart transplant for waitlisted adults
by BMI at listing. Observations censored on December 31, 2016; Kaplan-
Meier competing risk methods used to estimate time to transplant. Analysis
performed per candidate, not per listing. If an estimate is not plotted, 50% of
the cohort listed in that year had not undergone transplant by the censoring
date. Only the first transplant is counted.
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FigureHR 19. Percentage of adultswhounderwent deceased donor heart
transplant within a given time period of listing. Candidates concurrently
listed at more than one center are counted once, from the time of earliest
listing to the time of latest removal.
No data15.4 100.039.9 46.9 58.2 64.9
FigureHR 20. Percentage of adultswhounderwent deceased donor heart
transplant within 1 year of listing in 2015 by DSA. Candidates listed concur-
rently in a single DSA are counted once in that DSA, from the time of earliest
listing to the time of latest removal; candidates listed in multiple DSAs are
counted separately per DSA.
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Figure HR 21. Pretransplant mortality rates among adults waitlisted for
heart transplant by age. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure are
not shown. Age is determined at the later of listing date or January 1 of the
given year.
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Figure HR 22. Pretransplant mortality rates among adults waitlisted for
heart transplant by race. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure are
not shown.
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Figure HR 23. Pretransplant mortality rates among adults waitlisted for
heart transplant by sex. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure are
not shown.
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Figure HR 24. Pretransplant mortality rates among adults waitlisted for
heart transplant by diagnosis. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure are
not shown. CAD, coronary artery disease.
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Figure HR 25. Pretransplant mortality rates among adults waitlisted for
heart transplant by medical urgency. Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Individ-
ual listings are counted separately. Rates with less than 10 patient-years of
exposure are not shown.
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Figure HR 26. Pretransplant mortality rates among adults waitlisted for
heart transplant byVADat listing. Mortality rates are computed as the num-
ber of deaths per 100 patient-years of waiting in the given year. Individual list-
ings are counted separately. Rates with less than 10 patient-years of exposure
are not shown. VAD, ventricular assist device.
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Figure HR 27. Pretransplant mortality rates among adults waitlisted for
heart transplant in 2015-2016, by DSA.Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Patients
censored at waitlist removal. Individual listings are counted separately. Rates
with less than 10 patient-years of exposure are not shown.
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Figure HR 28. Deaths within sixmonths after removal among adult heart
waitlist candidates. Denominator includes only candidates removed from
the waiting list for reasons other than transplant or death while on the list.
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Figure HR 29. Deceased heart donors by age. Deceased donors whose
hearts were recovered for transplant.
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Figure HR 30. Deceased heart donors by race. Deceased donors whose
hearts were recovered for transplant.
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Figure HR 31. Deceased donor heart donation rates (per 1000 deaths) by
state, 2013-2015. Numerator: Deceased donors aged < 70 years, by state of
death, whose heart was recovered for transplant from2013 through 2015. De-
nominator: US deaths aged < 70 years, by state of death, from 2013 through
2015. State death data by age obtained through agreement with NAPHSIS
(https://www.naphsis.org/research-requests).
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Figure HR 32. Rates of hearts recovered for transplant and not trans-
planted by age. Percentages of hearts not transplanted out of all hearts re-
covered for transplant.
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Figure HR 33. Cause of death among deceased heart donors. Deceased
donors whose hearts were transplanted. CNS, central nervous system; CVA,
cerebrovascular accident.
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Figure HR 34. Total heart transplants. All heart transplant recipients, in-
cluding adult and pediatric, retransplant, and multi-organ recipients.
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FigureHR 35. Total heart transplants by age. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.
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FigureHR 36. Total heart transplants by sex. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.
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Figure HR 37. Total heart transplants by race. All heart transplant recipi-
ents, including adult and pediatric, retransplant, and multi-organ recipients.
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Figure HR 38. Total heart transplants by diagnosis. All heart transplant
recipients, including adult and pediatric, retransplant, and multi-organ recipi-
ents. CAD, coronary artery disease.
27
  
 
2004 2006 2008 2010 2012 2014 2016
Year
0
50
0
15
00
25
00
Tra
ns
pla
nts Status 1A
Status 1B
Status 2
Figure HR 39. Total heart transplants by medical urgency. All heart trans-
plant recipients, including adult and pediatric, retransplant, and multi-organ
recipients.
2004 2006 2008 2010 2012 2014 2016
Year
0
10
30
50
Pe
rce
nt IL2-RA
T-cell depleting
None
Figure HR 40. Induction agent use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. IL2-RA, interleukin-2
receptor antagonist.
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Figure HR 41. Calcineurin inhibitor use in adult heart transplant recipi-
ents. Immunosuppression at transplant reported to the OPTN.
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Figure HR 42. Anti-metabolite use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. Mycophenolate in-
cludes mycophenolate mofetil and mycophenolate sodium.
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Figure HR 43. mTOR inhibitor use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. One-year posttrans-
plant data are limited to patients alive with graft function at 1 year posttrans-
plant. mTOR, mammalian target of rapamycin.
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Figure HR 44. Steroid use in adult heart transplant recipients. Immuno-
suppression at transplant reported to theOPTN.One-year posttransplant data
are limited to patients alive with graft function at 1 year posttransplant.
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Figure HR 45. Total HLA A, B, and DR mismatches among adult deceased
donor heart transplant recipients, 2012-2016. Donor and recipient antigen
matching is based on OPTN antigen values and split equivalences policy as of
2016.
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Figure HR 46. Status of adult heart transplant recipients, 2014-2016, by
age. Age categories are not exclusive. All recipients aged 65 or older, for ex-
ample, are also included among those aged 60 or older and 50 or older.
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Figure HR 47. Annual adult heart transplant center volumes, by per-
centile. Annual volume data are limited to recipients aged 18 or older.
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FigureHR 48. Distribution of adult heart transplants by percentile of cen-
ter volume. Percentiles are based on annual volume data among recipients
aged 18 or older.
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Figure HR 49. Patient survival among adult heart transplant recipients,
2009-2011, by age. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only
the first is considered.
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Figure HR 50. Patient survival among adult heart transplant recipients,
2009-2011, by race. Patient survival estimated using unadjusted Kaplan-
Meier methods. For recipients of more than one transplant during the period,
only the first is considered.
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Figure HR 51. Patient survival among adult heart transplant recipients,
2009-2011, by sex. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only
the first is considered.
0 12 24 36 48 60
Months posttransplant
75
80
85
90
95
10
0
Pe
rce
nt VAD
IABP
Neither
Figure HR 52. Patient survival among adult heart transplant recipients,
2009-2011, by circulatory support. Patient survival estimated using unad-
justed Kaplan-Meier methods. For recipients of more than one transplant
during the period, only the first is considered. Ventricular assist device (VAD)
status at time of transplant. IABP, intra-aortic balloon pump.
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Figure HR 53. Patient survival among adult heart transplant recipients,
2009-2011, by first vs. retransplant. Patient survival estimated using un-
adjusted Kaplan-Meier methods. For recipients of more than one transplant
during the period, only the first is considered.
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Figure HR 54. Patient survival among adult heart transplant recipients,
2009-2011, bymedical urgency. Patient survival estimated using unadjusted
Kaplan-Meier methods. For recipients of more than one transplant during the
period, only the first is considered.
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Figure HR 55. Patient death among adult heart transplant recipients. All
adult recipients of deceased donor hearts, including multi-organ transplants.
Patients are followed until the earlier of death or December 31, 2016. Esti-
mates computed with Cox proportional hazards models adjusted for age, sex,
and race.
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Figure HR 56. Recipients alive with a functioning heart graft on June 30
of the year, by age at transplant. Recipients are assumed to be alive with
function unless a death or graft failure is recorded. A recipientmay experience
a graft failure and be removed from the cohort, undergo retransplant, and re-
enter the cohort.
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Figure HR 57. Incidence of acute rejection by 1 year posttransplant
among adult heart transplant recipients by age. Acute rejection is defined
as a record of acute or hyperacute rejection, as reported on the OPTN Trans-
plant Recipient Registration or Transplant Recipient Follow-up Form. Only the
first rejection event is counted. Cumulative incidence is estimated using the
Kaplan-Meier competing risk method.
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Figure HR 58. Incidence of PTLD among adult heart transplant recipients
by recipient EBV status at transplant, 2010-2014. Cumulative incidence is
estimated using the Kaplan-Meier competing risk method. PTLD is identified
as a reported complication or cause of death on the OPTN Transplant Recip-
ient Follow-up Form or the Posttransplant Malignancy Form as polymorphic
PTLD, monomorphic PTLD, or Hodgkin disease. Only the earliest date of PTLD
diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lym-
phoproliferative disorder.
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Figure HR 59. One-year cumulative incidence of death by cause among
adult heart recipients, 2014-2015. Primary cause of death is as reported
on the OPTN Transplant Recipient Registration and Follow-up Forms. Other
causes of death include hemorrhage, trauma, nonadherence, unspecified
other, unknown, etc. Cumulative incidence is estimated using Kaplan-Meier
competing risk methods.
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Figure HR 60. Five-year cumulative incidence of death by cause among
adult heart recipients, 2010-2011. Primary cause of death is as reported
on the OPTN Transplant Recipient Registration and Follow-up Forms. Other
causes of death include hemorrhage, trauma, nonadherence, unspecified
other, unknown, etc. Cumulative incidence is estimated using Kaplan-Meier
competing risk methods.
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Figure HR 61. New pediatric candidates added to the heart transplant
waiting list. A new candidate is one who first joined the list during the given
year, without having been listed in a previous year. Previously listed candi-
dates who underwent transplant and subsequently relisted are considered
new. Candidates concurrently listed at multiple centers are counted once. Ac-
tive and inactive patients are included. Age determined at listing.
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Figure HR 62. Pediatric candidates listed for heart transplant on De-
cember 31 each year. Candidates concurrently listed at multiple centers are
counted once. Those with concurrent listings and active at any program are
considered active.
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FigureHR63. Distribution of pediatric candidateswaiting for heart trans-
plant by age. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Age is
determined at the later of listing date or January 1 of the given year. Active
and inactive candidates are included.
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FigureHR64. Distribution of pediatric candidateswaiting for heart trans-
plant by race. Candidates waiting for transplant any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Active
and inactive candidates are included.
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FigureHR65. Distribution of pediatric candidateswaiting for heart trans-
plant by diagnosis. Candidates waiting for transplant any time in the given
year. Candidates listed concurrently at multiple centers are counted once. Ac-
tive and inactive candidates are included. CM, cardiomyopathy.
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FigureHR66. Distribution of pediatric candidateswaiting for heart trans-
plant bywaiting time. Candidateswaiting for transplant any time in the given
year. Candidates listed concurrently at multiple centers are counted once.
Time on thewaiting list is determined at the earlier of December 31 or removal
from the waiting list. Active and inactive candidates are included.
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FigureHR67. Distribution of pediatric candidateswaiting for heart trans-
plant by medical urgency. Candidates waiting for transplant any time in the
given year. Candidates listed concurrently at multiple centers are counted
once. Medical urgency status is the most severe during the year. Active and
inactive patients are included.
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Figure HR 68. Three-year outcomes for newly listed pediatric candidates
waiting for heart transplant, 2013. Pediatric candidates who joined the
waitlist in 2013. Candidates concurrently listed at more than one center are
counted once, from the time of earliest listing to the time of latest removal.
DD, deceased donor.
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Figure HR 69. Heart transplant rates among active pediatric waitlist can-
didates by age. Transplant rates are computed as the number of deceased
donor transplants per 100 patient-years of active waiting in a given year. Indi-
vidual listings are counted separately. Age is determined at the later of listing
date or January 1 of the given year. Rates with less than 10 patient-years of
exposure are not shown.
2005-06 2009-10 2013-14
Year
0
10
20
30
40
50
60
70
De
ath
s p
er 
10
0 w
ait
list
 ye
ars
< 1
1-5
6-10
11-17
All
Figure HR 70. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by age. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings are
counted separately. Age is determined at the later of listing date or January
1 of the given year. Rates with less than 10 patient-years of exposure are not
shown.
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Figure HR 71. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by race. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure are
not shown.
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Figure HR 72. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by diagnosis. Mortality rates are computed as the num-
ber of deaths per 100 patient-years of waiting in the given year. Individual list-
ings are counted separately. Rates with less than 10 patient-years of exposure
are not shown. CM, cardiomyopathy.
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Figure HR 73. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by medical urgency. Mortality rates are computed as
the number of deaths per 100 patient-years of waiting in the given year. Indi-
vidual listings are counted separately. Rates with less than 10 patient-years of
exposure are not shown.
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Figure HR 74. Pediatric heart transplants by age. All pediatric heart trans-
plant recipients, including retransplant, and multi-organ recipients.
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Figure HR 75. Number of centers performing pediatric and adult heart
transplants by center’s age mix. Adult centers transplanted only recipi-
ents aged 18 years or older. Functionally adult centers transplant 80% adults
or more, and the remainder were children aged 15-17 years. Mixed in-
cluded adults and children of any age groups. Child only centers transplanted
recipeints aged 0-17 years, and small number of adults up to age 21 years.
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Figure HR 76. Pediatric heart recipients at programs that perform 5 or
fewer pediatric transplants annually. Age groups are cumulative.
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Figure HR 77. Induction agent use in pediatric heart transplant re-
cipients. Immunosuppression at transplant reported to the OPTN. IL2-RA,
interleukin-2 receptor antagonist.
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Figure HR 78. Calcineurin inhibitor use in pediatric heart transplant re-
cipients. Immunosuppression at transplant reported to the OPTN.
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Figure HR 79. Anti-metabolite use in pediatric heart transplant recipi-
ents. Immunosuppression at transplant reported to the OPTN. Mycopheno-
late includes mycophenolate mofetil and mycophenolate sodium.
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FigureHR 80. mTOR inhibitor use in pediatric heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. One-year posttrans-
plant data are limited to patients alive with graft function at 1 year posttrans-
plant. mTOR, mammalian target of rapamycin.
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Figure HR 81. Steroid use in pediatric heart transplant recipients. Im-
munosuppression at transplant reported to the OPTN. One-year posttrans-
plant data are limited to patients alive with graft function at 1 year posttrans-
plant.
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Figure HR 82. Induction use by C/PRA among pediatric heart transplant
recipients, 2012-2016. Collection of calculated PRA (CPRA) began March 31,
2015. Prior to that, PRA class I and II values were used. IL2-RA, interleukin-2
receptor antagonist.
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Figure HR 83. Total HLA A, B, and DR mismatches among pediatric de-
ceased donor heart transplant recipients, 2012-2016. Donor and recipient
antigen matching is based on OPTN antigen values and split equivalences pol-
icy as of 2016.
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Figure HR 84. Incidence of acute rejection by 1 year posttransplant
among pediatric heart transplant recipients by age. Acute rejection is
defined as a record of acute or hyperacute rejection, as reported on the
OPTN Transplant Recipient Registration Form or Transplant Recipient Follow-
up Form. Only the first rejection event is counted. Cumulative incidence is
estimated using the Kaplan-Meier competing risk method.
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Figure HR 85. Incidence of PTLD among pediatric heart transplant recip-
ients by recipient EBV status at transplant, 2004-2014. Cumulative inci-
dence is estimated using the Kaplan-Meier competing risk method. Posttrans-
plant lymphoproliferative disorder (PTLD) is identified as a reported complica-
tion or cause of death on the OPTN Transplant Recipient Follow-up Form or
on the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic
PTLD, or Hodgkin disease. Only the earliest date of PTLD diagnosis is consid-
ered. EBV, Epstein-Barr virus.
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Figure HR 86. Patient death among pediatric heart transplant recipients.
All pediatric recipients of deceased donor hearts, including multi-organ trans-
plants. Patients are followed until the earlier of death or December 31, 2016.
Estimates computed with Cox proportional hazards models adjusted for age,
sex, and race.
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Figure HR 87. Patient survival among pediatric deceased donor heart
transplant recipients, 2004-2011, by age. Recipient survival estimated us-
ing unadjusted Kaplan-Meier methods.
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Figure HR 88. One-year cumulative incidence of death by cause among
pediatric heart recipients, 2014-2015. Primary cause of death is as re-
ported on the OPTN Transplant Recipient Registration and Follow-up Forms.
Other causes of death include hemorrhage, trauma, nonadherence, unspec-
ified other, unknown, etc. Cumulative incidence is estimated using Kaplan-
Meier competing risk methods.
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Figure HR 89. Five-year cumulative incidence of death by cause among
pediatric heart recipients, 2010-2011. Primary cause of death is as re-
ported on the OPTN Transplant Recipient Registration and Follow-up Forms.
Other causes of death include hemorrhage, trauma, nonadherence, unspec-
ified other, unknown, etc. Cumulative incidence is estimated using Kaplan-
Meier competing risk methods.
Characteristic 2006 2016N Percent N Percent
Age
18-34 years 265 10.4% 398 11.0%
35-49 years 602 23.6% 863 23.8%
50-64 years 1335 52.3% 1715 47.2%
≥ 65 years 349 13.7% 656 18.1%
Sex
Female 617 24.2% 858 23.6%
Male 1934 75.8% 2774 76.4%
Race/ethnicity
White 1885 73.9% 2227 61.3%
Black 410 16.1% 964 26.5%
Hispanic 182 7.1% 320 8.8%
Asian 54 2.1% 102 2.8%
Other/unknown 20 0.8% 19 0.5%
All candidates 2551 100.0% 3632 100.0%
Table HR 1Demographic characteristics of adults on the heart transplant
waiting list on December 31, 2006 and December 31, 2016. Candidates
waiting for transplant on December 31, 2006, and December 31, 2016, regard-
less of first listing date; multiple listings are collapsed.
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Characteristic 2006 2016N Percent N Percent
Diagnosis
Coronary artery disease 1063 41.7% 1148 31.6%
Cardiomyopathy 1147 45.0% 2094 57.7%
Congenital disease 135 5.3% 175 4.8%
Valvular disease 70 2.7% 36 1.0%
Other/unknown 136 5.3% 179 4.9%
Blood type
A 741 29.0% 1095 30.1%
B 257 10.1% 420 11.6%
AB 57 2.2% 86 2.4%
O 1496 58.6% 2031 55.9%
Medical urgency
Status 1A 66 2.6% 391 10.8%
Status 1B 266 10.4% 1626 44.8%
Status 2 911 35.7% 845 23.3%
Inactive status 1308 51.3% 770 21.2%
VAD at listing 145 5.7% 1166 32.1%
All candidates 2551 100.0% 3632 100.0%
Table HR 2 Clinical characteristics of adults on the heart transplant wait-
ing list on December 31, 2006 and December 31, 2016. Candidates waiting
for transplant on December 31, 2006, and December 31, 2016, regardless of
first listing date; multiple listings are collapsed. VAD, ventricular assist device.
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Characteristic 2006 2016N Percent N Percent
Transplant history
First 2478 97.1% 3515 96.8%
Retransplant 73 2.9% 117 3.2%
Wait time
< 1 year 919 36.0% 1826 50.3%
1-< 2 years 347 13.6% 785 21.6%
2-< 3 years 247 9.7% 449 12.4%
3-< 4 years 212 8.3% 225 6.2%
4-< 5 years 171 6.7% 126 3.5%
≥ 5 years 655 25.7% 221 6.1%
Tx type
Heart only 2378 93.2% 3362 92.6%
Heart-kidney 58 2.3% 191 5.3%
Heart-lung 104 4.1% 47 1.3%
Other 11 0.4% 32 0.9%
All candidates 2551 100.0% 3632 100.0%
Table HR 3 Listing characteristics of adults on the heart transplant wait-
ing list on December 31, 2006 and December 31, 2016. Candidates waiting
for transplant on December 31, 2006, and December 31, 2016, regardless of
first listing date; multiple listings are collapsed.
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Waiting list state 2014 2015 2016
Patients at start of year 3339 3625 3787
Patients added during year 3613 3622 3630
Patients removed during year 3319 3456 3785
Patients at end of year 3633 3791 3632
Table HR 4 Heart transplant waitlist activity among adults. Candidates
concurrently listed at more than one center are counted once, from the time
of earliest listing to the time of latest removal. Candidates who are listed, un-
dergo transplant, and are relisted are counted more than once. Candidates
are not considered to be on the list on the day they are removed; counts on
January 1 may differ from counts on December 31 of the prior year. Candi-
dates listed for multi-organ transplants are included.
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Removal reason 2014 2015 2016
Deceased donor transplant 2228 2331 2734
Patient died 377 393 322
Patient refused transplant 22 24 25
Improved, transplant not needed 201 162 187
Too sick for transplant 271 299 264
Other 220 247 252
TableHR 5Removal reason among adult heart transplant candidates. Re-
moval reason as reported to the OPTN. Candidates with death dates that pre-
cede removal dates are assumed to have died waiting.
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Support 2011 2016N Percent N Percent
Any life support 1553 78.7% 2372 85.8%
Intravenous inotropes 757 38.3% 974 35.2%
Left ventricular assist device 729 36.9% 1347 48.7%
Intra-aortic balloon pump 96 4.9% 211 7.6%
Right ventricular assist device 68 3.4% 39 1.4%
Ventilator 53 2.7% 36 1.3%
Total artificial heart 31 1.6% 38 1.4%
Extra corporeal membrane oxygenation 14 0.7% 33 1.2%
Prostaglandins 10 0.5% 0 0.0%
Inhaled NO 4 0.2% 3 0.1%
Table HR 6 Adult heart recipients on circulatory support before trans-
plant. Patients may have more than one type of circulatory support.
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Characteristic 2006 2016N Percent N Percent
Age
18-34 years 234 12.3% 296 10.7%
35-49 years 453 23.8% 542 19.6%
50-64 years 973 51.1% 1368 49.5%
≥65 years 243 12.8% 558 20.2%
Sex
Female 432 22.7% 722 26.1%
Male 1471 77.3% 2042 73.9%
Race/ethnicity
White 1333 70.0% 1744 63.1%
Black 340 17.9% 620 22.4%
Hispanic 156 8.2% 261 9.4%
Asian 63 3.3% 120 4.3%
Other/unknown 11 0.6% 19 0.7%
Insurance
Private 1056 55.5% 1205 43.6%
Medicare 536 28.2% 1082 39.1%
Medicaid 227 11.9% 325 11.8%
Other government 55 2.9% 96 3.5%
Unknown 29 1.5% 56 2.0%
All recipients 1903 100.0% 2764 100.0%
Table HR 7 Demographic characteristics of adult heart transplant recip-
ients, 2006 and 2016. Adult heart transplant recipients, including retrans-
plants.
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Characteristic 2006 2016N Percent N Percent
Diagnosis
Coronary artery disease 796 41.8% 917 33.2%
Cardiomyopathy 951 50.0% 1680 60.8%
Congenital disease 70 3.7% 79 2.9%
Valvular disease 48 2.5% 33 1.2%
Other/unknown 38 2.0% 55 2.0%
Blood type
A 813 42.7% 1094 39.6%
B 265 13.9% 427 15.4%
AB 83 4.4% 158 5.7%
O 742 39.0% 1085 39.3%
Medical urgency
Status 1A 705 37.0% 1863 67.4%
Status 1B 799 42.0% 837 30.3%
Status 2 399 21.0% 64 2.3%
On VAD 457 24.0% 1438 52.0%
CPRA
< 1% 1171 61.5% 1335 48.3%
1-< 20% 341 17.9% 329 11.9%
20-< 80% 195 10.2% 475 17.2%
80-< 98% 52 2.7% 88 3.2%
98-100% 30 1.6% 48 1.7%
Unknown 114 6.0% 489 17.7%
All recipients 1903 100.0% 2764 100.0%
Table HR 8 Clinical characteristics of adult heart transplant recipients,
2006 and 2016. Adult heart transplant recipients, including retransplants.
Ventricular assist device (VAD) information is from the OPTN Transplant Re-
cipient Registration Form and includes left VAD, right VAD, total artificial heart,
and left + right VAD. Collection of calculated PRA (CPRA) beganMarch 31, 2015.
Prior to that, PRA class I and II values were used.
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Characteristic 2006 2016N Percent N Percent
Wait time
< 31 days 676 35.5% 649 23.5%
31-60 days 302 15.9% 339 12.3%
61-90 days 196 10.3% 214 7.7%
3-< 6 months 300 15.8% 463 16.8%
6-< 12 months 219 11.5% 447 16.2%
1-< 2 years 125 6.6% 390 14.1%
≥ 2 years 85 4.5% 262 9.5%
Transplant history
First 1837 96.5% 2691 97.4%
Retransplant 66 3.5% 73 2.6%
Tx type
Heart only 1835 96.4% 2589 93.7%
Heart-lung 24 1.3% 17 0.6%
Heart-kidney 39 2.0% 139 5.0%
Heart-liver 4 0.2% 18 0.7%
Other 1 0.1% 1 0.0%
All recipients 1903 100.0% 2764 100.0%
Table HR 9 Transplant characteristics of adult heart transplant recipi-
ents, 2006 and 2016. Adult heart transplant recipients, including retrans-
plants.
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Donor Recipient CMV EBV HIV
D- R- 9.1% 0.7% 95.6%
D- R+ 12.7% 5.0% 0.3%
D- R unk 16.6% 0.6% 3.1%
D+ R- 13.5% 9.8% 0.0%
D+ R+ 21.3% 75.3% 0.0%
D+ R unk 26.4% 8.4% 0.0%
D unk R- 0.1% 0.0% 1.1%
D unk R+ 0.1% 0.2% 0.0%
D unk R unk 0.3% 0.0% 0.0%
Table HR 10 Adult heart donor-recipient serology matching, 2012-2016.
Donor serology is reported on the OPTN Donor Registration Form and recipi-
ent serology on the OPTN Transplant Recipient Registration Form. There may
be multiple fields per serology. Any evidence for a positive serology is treated
as positive for that serology. If all fields are unknown, incomplete, or pending,
the person is categorized as unknown for that serology; otherwise, serology
is assumed negative. CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, hu-
man immunodeficiency virus.
62
  
 
Characteristic 2006 2016N Percent N Percent
Age
< 1 year 31 12.4% 53 16.2%
1-5 years 74 29.5% 102 31.2%
6-10 years 67 26.7% 69 21.1%
11-17 years 79 31.5% 103 31.5%
Sex
Female 114 45.4% 145 44.3%
Male 137 54.6% 182 55.7%
Race/ethnicity
White 151 60.2% 168 51.4%
Black 44 17.5% 68 20.8%
Hispanic 43 17.1% 66 20.2%
Asian 10 4.0% 14 4.3%
Other/unknown 3 1.2% 11 3.4%
All candidates 251 100.0% 327 100.0%
Table HR 11 Demographic characteristics of pediatric candidates on the
heart transplant waiting list on December 31, 2006, December 31, 2011,
and December 31, 2016. Candidates aged younger than 18 years waiting for
transplant on December 31 of given year, regardless of first listing date; mul-
tiple listings are collapsed. Age calculated at snapshot.
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Characteristic 2006 2016N Percent N Percent
Diagnosis
Congenital defect 99 39.4% 181 55.4%
Idiopathic dilated CM 62 24.7% 51 15.6%
Familial dilated CM 2 0.8% 7 2.1%
Idiopathic restrictive CM 14 5.6% 19 5.8%
Myocarditis 14 5.6% 4 1.2%
Other/unknown 60 23.9% 65 19.9%
Blood type
A 76 30.3% 82 25.1%
B 17 6.8% 54 16.5%
AB 7 2.8% 6 1.8%
O 151 60.2% 185 56.6%
Medical urgency
Status 1A 33 13.1% 76 23.2%
Status 1B 27 10.8% 67 20.5%
Status 2 52 20.7% 93 28.4%
Inactive status 139 55.4% 91 27.8%
VAD at listing 8 3.2% 20 6.1%
All candidates 251 100.0% 327 100.0%
Table HR 12 Clinical characteristics of pediatric candidates on the heart
transplantwaiting list on December 31, 2006, December 31, 2011, andDe-
cember 31, 2016. Candidates aged younger than 18 years waiting for trans-
plant on December 31, 2006, and December 31, 2016, regardless of first listing
date; multiple listings are collapsed. CM, cardiomyopathy; VAD, ventricular as-
sist device.
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Characteristic 2006 2016N Percent N Percent
Transplant history
First 230 91.6% 307 93.9%
Retransplant 21 8.4% 20 6.1%
Wait time
< 1 year 124 49.4% 203 62.1%
1-< 2 years 31 12.4% 53 16.2%
2-< 3 years 25 10.0% 33 10.1%
3-< 4 years 10 4.0% 14 4.3%
4-< 5 years 14 5.6% 13 4.0%
≥ 5 years 47 18.7% 11 3.4%
Tx type
Heart only 229 91.2% 325 99.4%
Heart-kidney 3 1.2% 1 0.3%
Heart-lung 18 7.2% 1 0.3%
Other 1 0.4% 0 0.0%
All candidates 251 100.0% 327 100.0%
Table HR 13 Listing characteristics of pediatric candidates on the heart
transplantwaiting list on December 31, 2006, December 31, 2011, andDe-
cember 31, 2016. Candidates aged younger than 18 years waiting for trans-
plant on December 31, 2006, and December 31, 2016, regardless of first listing
date; multiple listings are collapsed.
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Waiting list state 2014 2015 2016
Patients at start of year 349 361 368
Patients added during year 593 644 626
Patients removed during year 579 635 627
Patients at end of year 363 370 367
Table HR 14 Heart transplant waitlist activity among pediatric candi-
dates. Candidates concurrently listed at more than one center are counted
once, from the time of earliest listing to the time of latest removal. Candi-
dates who are listed, undergo transplant, and are relisted are counted more
than once. Candidates are not considered to be on the list on the day they are
removed; counts on January 1 may differ from counts on December 31 of the
prior year. Candidates listed for multi-organ transplants are included.
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Removal reason 2014 2015 2016
Deceased donor transplant 422 463 460
Patient died 77 81 60
Patient refused transplant 1 3 2
Improved, transplant not needed 43 48 59
Too sick for transplant 29 23 29
Other 7 17 17
Table HR 15 Removal reason among pediatric heart transplant candi-
dates. Removal reason as reported to the OPTN. Candidates with death dates
that precede removal dates are assumed to have died waiting.
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Characteristic 2004-06 2014-16N Percent N Percent
Age
< 1 year 245 26.1% 377 28.7%
1-5 years 217 23.2% 308 23.4%
6-10 years 128 13.7% 184 14.0%
11-17 years 347 37.0% 446 33.9%
Sex
Female 439 46.9% 578 44.0%
Male 498 53.1% 737 56.0%
Race/ethnicity
White 520 55.5% 694 52.8%
Black 235 25.1% 241 18.3%
Hispanic 125 13.3% 285 21.7%
Asian 39 4.2% 57 4.3%
Other/unknown 18 1.9% 38 2.9%
Insurance
Private 480 51.2% 552 42.0%
Medicaid 384 41.0% 625 47.5%
Other government 51 5.4% 100 7.6%
Unknown 22 2.3% 38 2.9%
All recipients 937 100.0% 1315 100.0%
Table HR 16 Demographic characteristics of pediatric heart transplant
recipients, 2004-2006 and 2014-2016. Heart transplant recipients, including
retransplants.
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Characteristic 2004-06 2014-16N Percent N Percent
Diagnosis
Congenital defect 410 43.8% 632 48.1%
Idiopathic dilated CM 286 30.5% 322 24.5%
Familial dilated CM 33 3.5% 70 5.3%
Idiopathic restrictive CM 51 5.4% 67 5.1%
Myocarditis 25 2.7% 36 2.7%
Other/unknown 132 14.1% 188 14.3%
Blood type
A 349 37.2% 485 36.9%
B 116 12.4% 183 13.9%
AB 39 4.2% 48 3.7%
O 433 46.2% 599 45.6%
Medical urgency
Status 1A 671 71.6% 1115 84.8%
Status 1B 116 12.4% 162 12.3%
Status 2 150 16.0% 38 2.9%
On VAD 98 10.5% 312 23.7%
CPRA
< 1% 496 52.9% 556 42.3%
1-< 20% 154 16.4% 219 16.7%
20-< 80% 94 10.0% 279 21.2%
80-< 98% 30 3.2% 68 5.2%
98-100% 35 3.7% 28 2.1%
Unknown 128 13.7% 165 12.5%
All recipients 937 100.0% 1315 100.0%
Table HR 17 Clinical characteristics of pediatric heart transplant recip-
ients, 2004-2006 and 2014-2016. Heart transplant recipients, including re-
transplants. Collection of calculated PRA (CPRA) began March 31, 2015. Prior
to that, measured PRA values were used. CM, cardiomyopathy; VAD, ventric-
ular assist device.
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Characteristic 2004-06 2014-16N Percent N Percent
Wait time
< 31 days 428 45.7% 362 27.5%
31-60 days 184 19.6% 256 19.5%
61-90 days 98 10.5% 187 14.2%
3-< 6 months 133 14.2% 270 20.5%
6-< 12 months 56 6.0% 143 10.9%
1-< 2 years 23 2.5% 61 4.6%
≥ 2 years 15 1.6% 36 2.7%
ABO
Compatible/identical 912 97.3% 1244 94.6%
Incompatible 25 2.7% 71 5.4%
Transplant history
First 871 93.0% 1251 95.1%
Retransplant 66 7.0% 64 4.9%
Tx type
Heart only 910 97.1% 1300 98.9%
Heart-lung 17 1.8% 10 0.8%
Heart-kidney 7 0.7% 4 0.3%
Heart-liver 2 0.2% 1 0.1%
Other 1 0.1% 0 0.0%
All recipients 937 100.0% 1315 100.0%
Table HR 18 Transplant characteristics of pediatric heart transplant re-
cipients, 2004-2006 and 2014-2016. Heart transplant recipients, including re-
transplants.
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Support 2011 2016N Percent N Percent
Any life support 263 70.1% 339 76.2%
Intravenous inotropes 210 56.0% 235 52.8%
Ventilator 68 18.1% 74 16.6%
Left ventricular assist device 67 17.9% 100 22.5%
Right ventricular assist device 22 5.9% 14 3.1%
Extra corporeal membrane oxygenation 20 5.3% 17 3.8%
Prostaglandins 5 1.3% 18 4.0%
Intra-aortic balloon pump 1 0.3% 1 0.2%
Inhaled NO 1 0.3% 6 1.3%
Table HR 19 Pediatric heart recipients on circulatory support before
transplant. Patients may have more than one type of circulatory support.
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Donor Recipient CMV EBV
D- R- 17.3% 15.1%
D- R+ 10.7% 14.6%
D- R unk 21.1% 1.0%
D+ R- 17.0% 29.0%
D+ R+ 12.7% 37.4%
D+ R unk 20.4% 2.5%
D unk R- 0.4% 0.4%
D unk R+ 0.0% 0.1%
D unk R unk 0.4% 0.0%
Table HR 20 Pediatric heart donor-recipient serology matching,
2012-2016. Donor serology is reported on the OPTN Donor Registration
Form and recipient serology on the OPTN Transplant Recipient Registration
Form. There may be multiple fields per serology. Any evidence for a positive
serology is treated as positive for that serology. If all fields are unknown,
incomplete, or pending, the person is categorized as unknown for that
serology; otherwise, serology is assumed negative. CMV, cytomegalovirus;
EBV, Epstein-Barr virus.
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